Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of sequential FEC100 followed by ixabepilone versus epirubicin + docetaxel in operable breast cancer
2006-006494-24Phase 3Active
- Sponsor
- Unicancer
- Start
- Mar 2007
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of ixabepilone, epirubicin, docetaxel, fluorouracil and cyclophosphamide in breast cancer (2 arms), sponsored by Unicancer. Primary endpoint: Disease-free survival rate at 5 years. Started Mar 2007; status: active.
02
Drugs
ixabepiloneepirubicindocetaxelfluorouracilcyclophosphamide
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2006-006494-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-006494-24.